Iovance Biotherapeutics, Inc.
IOVA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001425205
No open-market purchases or sales by Iovance Biotherapeutics, Inc. insiders were filed in the last 90 days; 293 institutions reported holding it in 13F filings for Q2 2026, worth $1.19B in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Iovance Biotherapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Of which not filed for Q3 2021 | Q3 2021 | Change |
|---|---|---|---|---|
| Holders | 234 | 1 | 244 | +11 |
| Shares | 162.1M | 104.4K | 158.0M | −4.05M (−2.5%) |
| Value | $4.22B | $2.72M | $3.88B | −$329.9M (−7.8%) |
1 institution that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (34)
Institutions that held Iovance Biotherapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
Sold out (23)
Institutions that held Iovance Biotherapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Tekla Capital Management LLC | 468,538 | $12.2M |
| Jefferies Group LLC | 370,260 | $9.63M |
| Bank of Montreal | 134,046 | $3.55M |
| King Luther Capital Management Corp | 114,210 | $2.97M |
| DSAM Partners (London) Ltd | 81,627 | $2.12M |
| Maven Securities LTD | 60,046 | $1.66M |
| HN Saltoro Capital, LP | 46,419 | $1.21M |
| Discovery Value Fund | 35,437 | $922.0K |
| Premier Asset Management LLC | 28,760 | $748.0K |
| Cheyne Capital Management (UK) LLP | 25,000 | $651.0K |
| Marshall Wace, LLP | 17,867 | $465.0K |
| Natixis | 11,131 | $290.0K |
| Russell Investments Group, Ltd. | 11,073 | $287.0K |
| Bridgefront Capital, LLC | 9,391 | $244.0K |
| Raymond James Financial Services Advisors, Inc. | 8,888 | $231.0K |
| Claraphi Advisory Network, LLC | 8,218 | $214.0K |
| Kalos Management, Inc. | 8,450 | $212.0K |
| Crestwood Advisors Group LLC | 8,000 | $208.0K |
| Checchi Capital Advisers, LLC | 8,000 | $208.0K |
| Panagora Asset Management Inc | 3,336 | $87.0K |
| Adirondack Trust Co | 65 | $2.00K |
| Private Capital Group, LLC | 53 | $1.00K |
| TCI Wealth Advisors, Inc. | 17 | $0 |
Not filed for Q3 2021 yet (1)
Institutions that held Iovance Biotherapeutics, Inc. at the end of Q2 2021 and haven't filed a 13F for Q3 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Wexford Capital LP | 104,391 | $2.72M |